CPT code 81217: BRCA2 testing, known familial variant2026 Medicare lab fee · Clinical Laboratory Fee Schedule
Targeted BRCA2 analysis tests for a familial variant already identified, supporting evaluation of inherited breast and ovarian cancer risk.
Medicare pays $375.25 for 81217 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$375.25
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2020
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 81217 covers
BRCA2 known-familial-variant analysis examines a patient's DNA for a specific BRCA2 variant previously identified in the family. It is used in hereditary breast and ovarian cancer evaluation when testing for that established familial finding is indicated, rather than surveying the full BRCA2 gene. A clinical laboratory performs the genetic analysis and reports the result. This code distinguishes targeted familial-variant testing from broader BRCA2 sequence analysis and from testing for familial variants in other genes.
Report this service for targeted analysis of a known familial BRCA2 variant. Medicare pays the test through the Clinical Laboratory Fee Schedule (CLFS), which uses one national amount per code across states and localities, without geographic or office-versus-facility adjustment. The 2026 national CLFS amount is $375.25, unchanged since 2020. The test is paid only through the CLFS, not the physician fee schedule.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 81217
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 81217. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Excluded from the physician fee schedule
The physician fee schedule lists 81217 with status X (excluded by statute), so the test itself is paid only from the CLFS.
81217 on the lab fee schedule since 2020
81217 · CLFS 2026 Q4 (current)
$375.25
Unchanged since Jan 1, 2020
27 quarterly CLFS releases on file, first CLFS 2020 Q1. A code missing from a quarter wasn’t on that release.
81217 compared with similar tests
- 81216BRCA2 sequencingFull gene sequence$185.12
- Code 81217 targets a specific BRCA2 variant already identified in the family. Use 81216 for full BRCA2 gene sequence analysis.
- 81215BRCA1 testingKnown familial variant$375.25
- Code 81215 targets a known familial BRCA1 variant; 81217 targets a known familial BRCA2 variant.
- 81212BRCA testingThree specified variants$440.00
- Code 81212 tests specified BRCA1 and BRCA2 variants. Code 81217 targets a known familial BRCA2 variant.
81217 billing questions
When is this code appropriate instead of full BRCA2 sequencing?
Use this code when testing targets a specific BRCA2 variant already identified in the family. Code 81216 represents full BRCA2 gene sequence analysis.
Can this code be used for a known familial BRCA1 variant?
No. This code is for a known familial BRCA2 variant; code 81215 is for a known familial BRCA1 variant.
How does this differ from code 81212?
Code 81212 is for specified BRCA1 and BRCA2 variants. This code targets a known familial BRCA2 variant.
What documentation supports code selection?
The record should support that the analysis targets a BRCA2 variant already identified in the family and identify the patient tested.
How does Medicare pay for this test?
Medicare pays it through the CLFS at one national amount per code, without a locality or office-versus-facility adjustment.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 81217 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist